Oslo (Norway), January 6, 2017 – PCI Biotech (OSE: PCIB), a cancer focused biopharmaceutical company, and Ultimovacs, a pharmaceutical company developing novel immunotherapy against cancer, today announced that they are awarded NOK 500,000 for further development of the existing preclinical research collaboration. The purpose of the collaboration is to utilise the companies’ complementary scientific platforms to explore potential synergies and the grant will support these activities. The Innovation Norway grant of NOK 500,000 is awarded for 2017 and the grant is made available through Oslo Cancer Cluster, a Norwegian Centre of Expertise.
Please see attached press release for further details.
PCI Biotech Holding ASA, Ullernchausséen 64, N-0379 Oslo, Norway.
Per Walday, CEO, firstname.lastname@example.org, Mobile: +47 917 93 429